Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Revision History For: NNVC - NanoViricides, Inc.

16 Nov 2014 10:38 AM <--

Return to NNVC - NanoViricides, Inc.

EbolaCide2 - Plan of attack
Re: USAMRIID

Corinne (Scully) is gone and Gene (Olinger) is at the NIH virology labs
I'm in touch with Gene and would love to work with him.
We're shooting for a mid-November ship date but that's completely dependent on completing the synthesis of all the variants. Usually we make 8 variants, send them for testing, take the best two, expand them and make another eight.
This time, we're making many more and they'll all be tested during the same pass to save time.
If this works as we hope, I want to get EbolaCide to Africa ASAP!

EUGENE SEYMOUR - Chief Executive Officer & Director
October 31, 2014

Lab Facilities:
Present - bench top model:

New lab - walk-in hood about 10 feet high:

Dr. Diwan, President NNVC and inventor explains the underlying newly patented technology and other NNVC licensed patent applications

NanoViricides, Inc. (NNVC)
A typical nanoviricides drug is designed like a chemical missile. It has a number of recognition "ligands" on its surface, that are specific to a single type of virus, say HIV. They are like the GPS on a directed missile. They will identify the enemy and attach to specific "landing sites" on the enemy target. The nanoviricides drug, after landing, spreads itself all over the virus particle, and thus completely neutralizes and disables the virus particle from binding to its target, a human cell.

Employees: 6
(Millions)
Market Cap: $263.38
Shares Outstanding: 42.76
Float: 33.67

NanoViricides CEO's Letter to Shareholders, March 11, 2014

Officers and Executives

Dr. Anil R. Diwan
Chairman, President & Secretary

Ms. Meeta R. Vyas
Chief Financial Officer

Dr. Randall W. Barton
Chief Scientific Officer

Dr. Jayant Tatake
Vice President-Research & Development

Dr. Milton Boniuk
Independent Director

Dr. Eugene Seymour
Chief Executive Officer & Director

Mr. Stanley Glick
Independent Director

Dr. Mukund S. Kulkarni
Independent Director

Dr. Krishna Kumar Menon
Chief Regulatory Officer

IP
Solubilization and Targeted Delivery of Drugs with Selfassembling Amphiphilic Polymers